Acute Respiratory Distress Syndrome PDF

Preface

According to the American Lung Association, the incidence of acute respiratory distress syndrome (ARDS) is reaching toward 71 per 100,000 persons in the United States. Screenings of medical and surgical patients confirm the significant incidence and mortality. Onset of ARDS develops quickly, often within 24 to 48 hours of the injury or illness and overall mortality rates are nearly 50% of all cases. In patients who survive, recovery is a long process, with normal lung function resuming 6 to 12 months after the patient's initial victory.

There is currently no comprehensive book available to the clinician that gathers in one place the significant advances that have occurred since publication of Michael Matthay's 2003 Acute Respiratory Distress Syndrome. Lung clinicians and researchers, pulmonary and critical physicians, and all scientists working in lung disease require a single source guide to prediction and management of ARDS and treatment of the patient. This book will be a comprehensive review of both clinical and experimental paradigms of ARDS.

This new edition will review the current state-of-the-art paradigms and tenets in the field of ARDS. It is paramount to update the previous edition as the field continues to evolve with advancements with significant implications in patient care and treatment of ARDS. The chapters will address important aspects of both pathophysiology and pathogenesis of ARDS. Pathogenesis itself will be discussed in both experimental and clinical studies before discussion of pathogenesis of ventilator-induced lung injury and sepsis/ septic-induced lung injury.

Much progress has also been noted in various forms of therapy. Although the overall effectiveness of many therapies remain a topic of debate in competing studies, the latest methods are thoroughly presented including glucocorticoid therapy, surfactant therapy, prone position, forms of mechanical ventilation (invasive and noninvasive), and current research in the use of mesenchymal stem cells.

This edition covers new topics in addition to the important topics covered previously. These new areas have blossomed markedly in the past five years that warrant new chapters for this book, particularly predictive factors including gene expression profiling and biomarkers, and chemokines and cytokines in ARDS. Over 60% of ARDS patients develop nosocomial pulmonary infections and a new chapter is devoted to host defense mechanisms and infection prevention. We have also added key new chapters on the management of the ARDS patient, including cell-based therapy, fluid management in ARDS, and nonpulmonary and nonsepsis management. Additionally, chapters covering transfusion-related acute lung injury, vascular endothelium leakage, and the long-term clinical outcomes have been added to ensure the best in patient management and care.